 Michael Strong
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 24 | 2023 | 334 | 5.710 |
Why?
| | Genome, Bacterial | 13 | 2021 | 109 | 4.190 |
Why?
| | Mycobacterium | 11 | 2023 | 103 | 4.080 |
Why?
| | Mycobacterium tuberculosis | 17 | 2022 | 266 | 2.870 |
Why?
| | Nontuberculous Mycobacteria | 15 | 2023 | 206 | 2.780 |
Why?
| | Mycobacterium abscessus | 10 | 2023 | 97 | 2.330 |
Why?
| | Mycobacterium Infections | 6 | 2021 | 61 | 1.790 |
Why?
| | Cystic Fibrosis | 11 | 2023 | 964 | 1.330 |
Why?
| | Tuberculosis | 7 | 2022 | 240 | 1.320 |
Why?
| | Phylogeny | 14 | 2021 | 816 | 1.240 |
Why?
| | Genomics | 5 | 2021 | 706 | 1.090 |
Why?
| | Genome, Viral | 3 | 2021 | 124 | 1.070 |
Why?
| | Bacteriophages | 3 | 2022 | 76 | 1.030 |
Why?
| | Lung Diseases | 3 | 2022 | 718 | 0.980 |
Why?
| | Methylobacterium | 1 | 2023 | 4 | 0.950 |
Why?
| | Antitubercular Agents | 7 | 2021 | 163 | 0.900 |
Why?
| | Computational Biology | 7 | 2018 | 588 | 0.880 |
Why?
| | Genetic Variation | 7 | 2021 | 926 | 0.800 |
Why?
| | Viral Nonstructural Proteins | 1 | 2021 | 59 | 0.800 |
Why?
| | Whole Genome Sequencing | 2 | 2021 | 113 | 0.790 |
Why?
| | Lysogeny | 1 | 2020 | 3 | 0.770 |
Why?
| | Prophages | 1 | 2020 | 4 | 0.770 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 94 | 0.770 |
Why?
| | Sequence Analysis, DNA | 7 | 2022 | 755 | 0.760 |
Why?
| | Databases, Genetic | 3 | 2018 | 253 | 0.760 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 613 | 0.760 |
Why?
| | Bacterial Proteins | 10 | 2016 | 759 | 0.750 |
Why?
| | Viruses | 1 | 2021 | 96 | 0.730 |
Why?
| | Plasmids | 1 | 2020 | 355 | 0.720 |
Why?
| | Hawaii | 5 | 2023 | 36 | 0.680 |
Why?
| | Mutation | 3 | 2021 | 3457 | 0.670 |
Why?
| | Soil Microbiology | 2 | 2020 | 183 | 0.650 |
Why?
| | Drug Resistance, Bacterial | 7 | 2021 | 155 | 0.640 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2062 | 0.630 |
Why?
| | Cardiac Surgical Procedures | 2 | 2019 | 461 | 0.590 |
Why?
| | Respiratory System | 1 | 2017 | 141 | 0.560 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 251 | 0.560 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2016 | 63 | 0.550 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2021 | 333 | 0.540 |
Why?
| | Software | 4 | 2022 | 613 | 0.530 |
Why?
| | Cross Infection | 3 | 2021 | 205 | 0.470 |
Why?
| | Systems Biology | 1 | 2014 | 57 | 0.470 |
Why?
| | Microbiota | 1 | 2021 | 656 | 0.470 |
Why?
| | Skin Diseases, Bacterial | 1 | 2013 | 24 | 0.470 |
Why?
| | DNA, Bacterial | 4 | 2021 | 314 | 0.460 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2016 | 112 | 0.450 |
Why?
| | Humans | 51 | 2023 | 118972 | 0.450 |
Why?
| | Respiratory Tract Diseases | 1 | 2014 | 143 | 0.430 |
Why?
| | Molybdenum | 2 | 2021 | 9 | 0.390 |
Why?
| | Metagenomics | 2 | 2021 | 134 | 0.380 |
Why?
| | Genotype | 4 | 2019 | 1882 | 0.370 |
Why?
| | Sputum | 6 | 2021 | 290 | 0.370 |
Why?
| | Microbial Sensitivity Tests | 3 | 2021 | 302 | 0.360 |
Why?
| | Genetic Predisposition to Disease | 2 | 2016 | 2275 | 0.360 |
Why?
| | Lung | 6 | 2023 | 3664 | 0.340 |
Why?
| | RNA | 1 | 2014 | 833 | 0.310 |
Why?
| | Genes, Bacterial | 4 | 2017 | 162 | 0.300 |
Why?
| | United States | 9 | 2022 | 12555 | 0.290 |
Why?
| | Chromosome Mapping | 2 | 2023 | 510 | 0.280 |
Why?
| | Bacterial Typing Techniques | 2 | 2017 | 43 | 0.270 |
Why?
| | Proteomics | 3 | 2006 | 876 | 0.270 |
Why?
| | Disease Outbreaks | 2 | 2021 | 322 | 0.270 |
Why?
| | Tuberculosis, Multidrug-Resistant | 3 | 2016 | 45 | 0.260 |
Why?
| | Cluster Analysis | 4 | 2014 | 481 | 0.260 |
Why?
| | Proteins | 2 | 2013 | 938 | 0.260 |
Why?
| | Soil | 3 | 2022 | 181 | 0.250 |
Why?
| | Evolution, Molecular | 2 | 2021 | 454 | 0.250 |
Why?
| | Virulence | 3 | 2020 | 240 | 0.250 |
Why?
| | Data Accuracy | 1 | 2023 | 56 | 0.230 |
Why?
| | Multigene Family | 1 | 2003 | 200 | 0.220 |
Why?
| | Immunity, Innate | 2 | 2021 | 745 | 0.220 |
Why?
| | Protein Conformation, beta-Strand | 1 | 2021 | 16 | 0.210 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2021 | 15 | 0.210 |
Why?
| | Furin | 1 | 2021 | 13 | 0.210 |
Why?
| | Asia | 1 | 2021 | 54 | 0.210 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 51 | 0.200 |
Why?
| | Africa | 1 | 2021 | 100 | 0.200 |
Why?
| | Alanine | 1 | 2021 | 102 | 0.200 |
Why?
| | Epidemiological Monitoring | 1 | 2021 | 49 | 0.200 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 101 | 0.200 |
Why?
| | Genome Size | 1 | 2020 | 10 | 0.200 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 453 | 0.200 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 138 | 0.190 |
Why?
| | Europe | 1 | 2021 | 356 | 0.190 |
Why?
| | Models, Molecular | 3 | 2016 | 1435 | 0.190 |
Why?
| | Amino Acid Substitution | 1 | 2021 | 276 | 0.190 |
Why?
| | Killer Cells, Natural | 2 | 2014 | 381 | 0.190 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 522 | 0.190 |
Why?
| | Bacteriological Techniques | 1 | 2021 | 66 | 0.190 |
Why?
| | Water Pollution | 1 | 2020 | 7 | 0.190 |
Why?
| | Metagenome | 1 | 2021 | 121 | 0.190 |
Why?
| | Water Quality | 1 | 2020 | 29 | 0.190 |
Why?
| | Antigens, Bacterial | 2 | 2014 | 116 | 0.180 |
Why?
| | Immune Evasion | 1 | 2020 | 48 | 0.180 |
Why?
| | Protein Binding | 2 | 2021 | 1975 | 0.180 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2020 | 78 | 0.180 |
Why?
| | Pneumonia | 2 | 2023 | 592 | 0.180 |
Why?
| | Membrane Lipids | 1 | 2020 | 88 | 0.170 |
Why?
| | Databases, Factual | 2 | 2021 | 1231 | 0.170 |
Why?
| | Gene Expression Regulation, Bacterial | 4 | 2016 | 279 | 0.170 |
Why?
| | Protein Conformation | 2 | 2016 | 848 | 0.170 |
Why?
| | Gene Expression Profiling | 6 | 2016 | 1597 | 0.160 |
Why?
| | Phospholipids | 1 | 2020 | 208 | 0.160 |
Why?
| | Binding Sites | 1 | 2021 | 1224 | 0.160 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1510 | 0.160 |
Why?
| | Mycolic Acids | 1 | 2017 | 6 | 0.160 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.160 |
Why?
| | Virus Diseases | 1 | 2020 | 198 | 0.160 |
Why?
| | Base Composition | 1 | 2017 | 77 | 0.160 |
Why?
| | Oregon | 1 | 2017 | 69 | 0.150 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 104 | 0.150 |
Why?
| | Water Supply | 1 | 2017 | 71 | 0.150 |
Why?
| | Surgical Equipment | 1 | 2016 | 13 | 0.150 |
Why?
| | Brazil | 2 | 2014 | 109 | 0.150 |
Why?
| | DNA Gyrase | 1 | 2016 | 12 | 0.140 |
Why?
| | RNA, Viral | 1 | 2020 | 572 | 0.140 |
Why?
| | Equipment Contamination | 1 | 2016 | 55 | 0.140 |
Why?
| | Fluoroquinolones | 1 | 2016 | 42 | 0.140 |
Why?
| | Gene Expression | 1 | 2021 | 1489 | 0.140 |
Why?
| | Web Browser | 1 | 2015 | 16 | 0.140 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2015 | 17 | 0.140 |
Why?
| | Antiviral Agents | 1 | 2021 | 654 | 0.140 |
Why?
| | Catalase | 1 | 2016 | 123 | 0.140 |
Why?
| | Gene Ontology | 1 | 2015 | 55 | 0.140 |
Why?
| | Isoniazid | 1 | 2016 | 53 | 0.140 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 91 | 0.140 |
Why?
| | Rifampin | 1 | 2016 | 69 | 0.130 |
Why?
| | Housing | 1 | 2016 | 123 | 0.130 |
Why?
| | Bacterial Toxins | 1 | 2016 | 106 | 0.130 |
Why?
| | Adaptation, Physiological | 2 | 2016 | 502 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 514 | 0.130 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 381 | 0.130 |
Why?
| | Data Mining | 1 | 2016 | 113 | 0.130 |
Why?
| | Viral Core Proteins | 1 | 2014 | 21 | 0.130 |
Why?
| | Adaptive Immunity | 1 | 2016 | 161 | 0.120 |
Why?
| | Tuberculosis Vaccines | 1 | 2014 | 3 | 0.120 |
Why?
| | Biofilms | 1 | 2016 | 231 | 0.120 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2020 | 451 | 0.120 |
Why?
| | Genetic Linkage | 2 | 2006 | 321 | 0.120 |
Why?
| | DNA Repeat Expansion | 1 | 2013 | 5 | 0.120 |
Why?
| | Operon | 2 | 2003 | 62 | 0.120 |
Why?
| | Transcriptome | 2 | 2015 | 756 | 0.110 |
Why?
| | Galectins | 1 | 2013 | 23 | 0.110 |
Why?
| | Conserved Sequence | 2 | 2003 | 219 | 0.110 |
Why?
| | Phenotype | 3 | 2016 | 3003 | 0.110 |
Why?
| | Virulence Factors | 1 | 2014 | 140 | 0.110 |
Why?
| | Hepacivirus | 1 | 2014 | 230 | 0.110 |
Why?
| | Epidemics | 1 | 2013 | 70 | 0.110 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 126 | 0.110 |
Why?
| | Biomedical Research | 1 | 2018 | 612 | 0.100 |
Why?
| | Neurodegenerative Diseases | 1 | 2013 | 99 | 0.100 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 142 | 0.100 |
Why?
| | Adult | 9 | 2023 | 31512 | 0.100 |
Why?
| | DNA, Viral | 1 | 2012 | 356 | 0.090 |
Why?
| | Colorado | 4 | 2022 | 4196 | 0.090 |
Why?
| | Base Sequence | 1 | 2013 | 2159 | 0.090 |
Why?
| | Time Factors | 2 | 2021 | 6412 | 0.090 |
Why?
| | Aged | 6 | 2021 | 19657 | 0.090 |
Why?
| | Species Specificity | 2 | 2020 | 565 | 0.080 |
Why?
| | Middle Aged | 7 | 2021 | 27617 | 0.080 |
Why?
| | Transcription, Genetic | 4 | 2016 | 1323 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2021 | 344 | 0.080 |
Why?
| | Signal Transduction | 2 | 2016 | 4709 | 0.080 |
Why?
| | Public Health | 1 | 2012 | 450 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2021 | 3171 | 0.080 |
Why?
| | Cell Wall | 2 | 2006 | 53 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2445 | 0.070 |
Why?
| | Treatment Failure | 2 | 2021 | 341 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4552 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2021 | 6561 | 0.070 |
Why?
| | Uganda | 2 | 2016 | 74 | 0.070 |
Why?
| | Solubility | 1 | 2006 | 235 | 0.070 |
Why?
| | Biomarkers | 1 | 2015 | 3588 | 0.070 |
Why?
| | Cloning, Molecular | 1 | 2006 | 546 | 0.060 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 422 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2016 | 9342 | 0.060 |
Why?
| | Iron | 2 | 2022 | 248 | 0.060 |
Why?
| | Protein Kinases | 2 | 2016 | 310 | 0.060 |
Why?
| | Glutamate-Ammonia Ligase | 1 | 2003 | 5 | 0.060 |
Why?
| | Galactans | 1 | 2003 | 4 | 0.060 |
Why?
| | Proteome | 2 | 2006 | 353 | 0.060 |
Why?
| | Male | 7 | 2022 | 57801 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2018 | 2874 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 770 | 0.060 |
Why?
| | Genome | 1 | 2006 | 277 | 0.060 |
Why?
| | Dust | 1 | 2023 | 88 | 0.060 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2014 | 204 | 0.060 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 93 | 0.050 |
Why?
| | Female | 7 | 2021 | 61564 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2459 | 0.050 |
Why?
| | Oxides | 1 | 2022 | 42 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 726 | 0.050 |
Why?
| | Clarithromycin | 1 | 2021 | 28 | 0.050 |
Why?
| | Armadillos | 1 | 2021 | 2 | 0.050 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 7 | 0.050 |
Why?
| | Macrophages | 2 | 2020 | 1324 | 0.050 |
Why?
| | Macrolides | 1 | 2021 | 57 | 0.050 |
Why?
| | Clone Cells | 1 | 2021 | 248 | 0.050 |
Why?
| | Bioreactors | 1 | 2021 | 45 | 0.050 |
Why?
| | Cell Membrane | 2 | 2020 | 710 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 172 | 0.050 |
Why?
| | Water | 1 | 2023 | 425 | 0.050 |
Why?
| | Smokers | 1 | 2021 | 149 | 0.050 |
Why?
| | Microbial Viability | 1 | 2021 | 81 | 0.050 |
Why?
| | Chromatography, Thin Layer | 1 | 2020 | 23 | 0.050 |
Why?
| | THP-1 Cells | 1 | 2020 | 20 | 0.050 |
Why?
| | Glycolipids | 1 | 2020 | 37 | 0.050 |
Why?
| | Cathelicidins | 1 | 2020 | 39 | 0.050 |
Why?
| | Genetics, Population | 1 | 2021 | 207 | 0.040 |
Why?
| | DNA-Binding Proteins | 2 | 2016 | 1346 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 310 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 663 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2016 | 2657 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2021 | 3730 | 0.040 |
Why?
| | Gambia | 1 | 2016 | 12 | 0.040 |
Why?
| | Hospitals | 1 | 2021 | 598 | 0.040 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 359 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2023 | 867 | 0.040 |
Why?
| | Regulon | 1 | 2016 | 31 | 0.040 |
Why?
| | Nitrogen Oxides | 1 | 2016 | 56 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 73 | 0.030 |
Why?
| | India | 1 | 2016 | 141 | 0.030 |
Why?
| | Risk Factors | 2 | 2021 | 9000 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 87 | 0.030 |
Why?
| | Escherichia coli | 1 | 2020 | 758 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 10793 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2326 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 18480 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 175 | 0.030 |
Why?
| | Specimen Handling | 1 | 2016 | 165 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 187 | 0.030 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 69 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 34 | 0.030 |
Why?
| | Multilocus Sequence Typing | 1 | 2014 | 12 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2016 | 300 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 76 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 473 | 0.030 |
Why?
| | Extracellular Space | 1 | 2014 | 127 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2014 | 151 | 0.030 |
Why?
| | C9orf72 Protein | 1 | 2013 | 11 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 315 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1474 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2017 | 405 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2014 | 278 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 89 | 0.030 |
Why?
| | United Kingdom | 1 | 2014 | 236 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1129 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 122 | 0.030 |
Why?
| | Muromegalovirus | 1 | 2013 | 13 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1012 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 29 | 0.030 |
Why?
| | tau Proteins | 1 | 2013 | 78 | 0.030 |
Why?
| | Receptors, Virus | 1 | 2013 | 78 | 0.030 |
Why?
| | Interleukin-15 | 1 | 2013 | 77 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 239 | 0.030 |
Why?
| | Interleukin-12 | 1 | 2013 | 110 | 0.030 |
Why?
| | Gene Deletion | 1 | 2014 | 361 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 188 | 0.030 |
Why?
| | Prospective Studies | 1 | 2023 | 6471 | 0.030 |
Why?
| | Hepatitis C | 1 | 2014 | 217 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 369 | 0.030 |
Why?
| | Drug Discovery | 1 | 2012 | 124 | 0.020 |
Why?
| | Genetic Testing | 1 | 2013 | 389 | 0.020 |
Why?
| | Mice | 2 | 2021 | 15520 | 0.020 |
Why?
| | Viral Proteins | 1 | 2012 | 296 | 0.020 |
Why?
| | Animals | 3 | 2021 | 33381 | 0.020 |
Why?
| | Hypoxia | 1 | 2016 | 963 | 0.020 |
Why?
| | Child | 2 | 2021 | 19129 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2871 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1055 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 2680 | 0.020 |
Why?
| | Vaccination | 1 | 2014 | 1222 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4077 | 0.020 |
Why?
| | Biological Transport | 1 | 2006 | 382 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2021 | 12978 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4596 | 0.020 |
Why?
| | DNA Repair | 1 | 2006 | 198 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 5116 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 4908 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2006 | 477 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 872 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 464 | 0.010 |
Why?
|
|
Strong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|